ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.

Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abgenix
• Collaborator: Immunex Corporation
• Treatments: Panitumumab

Criteria

Inclusion Criteria:

• Male 18 years of age or older

• Has tumor tissue available for diagnostics

• Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. Patients must continue on a LHRH analogue (unless the patient had an orchiectomy) throughout the course of the study

• ECOG score of 0 or 1

Exclusion Criteria:

• Any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior EGFr targeting agent)

• Prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed)

• Known to be HIV positive

• Myocardial infarction within one year prior to entering the study